ABYEX | VEMIX | ABYEX / VEMIX | |
Total Expense Ratio | 1.00 | 0.09 | 1,111% |
Annual Report Gross Expense Ratio | 1.40 | 0.09 | 1,556% |
Fund Existence | 14 years | 25 years | - |
Gain YTD | 14.636 | 17.423 | 84% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 5000000 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 143M | 130B | 0% |
Annual Yield % from dividends | 5.20 | 2.68 | 194% |
Returns for 1 year | 17.31 | 19.67 | 88% |
Returns for 3 years | 51.65 | 37.62 | 137% |
Returns for 5 years | 29.32 | 29.47 | 99% |
Returns for 10 years | 70.19 | 81.86 | 86% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
AGRYX | 144.00 | 0.30 | +0.21% |
AB Growth Advisor | |||
BADEX | 11.02 | 0.02 | +0.18% |
BlackRock Defensive Advantage EM Inv A | |||
SHSKX | 65.13 | N/A | N/A |
BlackRock Health Sciences Opps K | |||
ANTUX | 10.39 | N/A | N/A |
American Century Non-US IntrsVal Inv | |||
DSMLX | 67.40 | -0.15 | -0.22% |
Touchstone Large Company Growth Instl |